HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.

Abstract
Neutropenia during chemotherapy has been reported to be a predictor of better survival in patients with several types of cancer, although there are no reports on stage III colorectal cancer (CRC). The purpose of this study was to examine the association between neutropenia and prognosis in stage III CRC patients receiving adjuvant chemotherapy consisting of oral uracil and tegafur (UFT) plus leucovorin (LV). We retrospectively analysed 123 patients with stage III CRC who received UFT/LV as adjuvant chemotherapy. The end-point was disease-free survival (DFS). Survival curves of the two categories (neutropenia absent vs. present) were estimated using the Kaplan-Meier method and compared by the log-rank test. We estimated the hazard ratio (HR) for DFS according to neutropenia after adjustment for covariates by multivariate analyses using Cox's regression analysis. A total of 33 (26.8%) patients experienced neutropenia. Patients without neutropenia showed a significantly lower DFS than those with neutropenia (3-year DFS 57.3% vs. 81.2%, P = 0.0213). By multivariate analysis, neutropenia and histological type were independent prognostic factors, with HR of 0.410 (neutropenia absent vs. present, P = 0.045) and 4.793 (well to moderately differentiated vs. poorly differentiated, P = 0.004) respectively. We demonstrated that neutropenia occurring during adjuvant chemotherapy consisting of UFT/LV may be a prognostic factor of recurrence in stage III CRC patients.
AuthorsT Sunaga, S Suzuki, M Kogo, T Kurihara, S Kaji, N Koike, N Harada, M Suzuki, Y Kiuchi
JournalEuropean journal of cancer care (Eur J Cancer Care (Engl)) Vol. 23 Issue 3 Pg. 394-400 (May 2014) ISSN: 1365-2354 [Electronic] England
PMID24033646 (Publication Type: Journal Article)
Copyright© 2013 John Wiley & Sons Ltd.
Chemical References
  • Tegafur
  • Uracil
  • Leucovorin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects)
  • Carcinoma (drug therapy, pathology)
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Colorectal Neoplasms (drug therapy, pathology)
  • Female
  • Humans
  • Leucovorin (administration & dosage)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neutropenia (chemically induced)
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Tegafur (administration & dosage)
  • Treatment Outcome
  • Uracil (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: